Liposomal encapsulated anti-cancer drugs

被引：259

作者：

Hofheinz, RD

Gnad-Vogt, SU

Beyer, U

Hochhaus, A

机构：

[1] Heidelberg Univ, Fak Klin Med Mannheim, Med Klin 3, Onkol Zentrum, D-68167 Mannheim, Germany

[2] Medac GMBH, Wedel, Germany

来源：

ANTI-CANCER DRUGS | 2005年 / 16卷 / 07期

关键词：

D O I：

10.1097/01.cad.0000167902.53039.5a

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced and versatile technology. Several formulations of liposomal anthracyclines are approved, e.g. for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin). Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anticancer agents.

引用

页码：691 / 707

页数：17

共 127 条

[1] Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials [J].

Alberts, DS ;

Muggia, FM ;

Carmichael, J ;

Winer, EP ;

Jahanzeb, M ;

Venook, AP ;

Skubitz, KM ;

Rivera, E ;

Sparano, JA ;

Dibella, NJ ;

Stewart, SJ ;

Kavanagh, JJ ;

Gabizon, AA .

SEMINARS IN ONCOLOGY, 2004, 31 (06) :53-90

[2]

Ali Shahid, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1345

[3] DIFFUSION OF UNIVALENT IONS ACROSS LAMELLAE OF SWOLLEN PHOSPHOLIPIDS [J].

BANGHAM, AD ;

STANDISH, MM ;

WATKINS, JC .

JOURNAL OF MOLECULAR BIOLOGY, 1965, 13 (01) :238-+

[4]

BARTELHEIM K, 2004, P AN M AM SOC CLIN, V22, P3079

[5] Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J].

Batist, G ;

Ramakrishnan, G ;

Rao, CS ;

Chandrasekharan, A ;

Gutheil, J ;

Guthrie, T ;

Shah, P ;

Khojasteh, A ;

Nair, MK ;

Hoelzer, K ;

Tkaczuk, K ;

Park, YC ;

Lee, LW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1444-1454

[6]

BEHRINGER DM, 2002, EJC SUPPL, V38, pP82

[7] Pharmacoeconomics of liposomal anthracycline therapy [J].

Bennett, CL ;

Calhoun, EA .

SEMINARS IN ONCOLOGY, 2004, 31 (06) :191-195

[8]

Billingham M., 1984, CANCER TREAT S, V3, P71

[9]

Bleyer WA, 1999, CLIN CANCER RES, V5, P3349

[10]

Boman NL, 1995, J LIPOS RES, V5, P523, DOI 10.3109/08982109509010240

← 1 2 3 4 5 6 7 8 9 10 →